Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Olodaterol
Drug ID BADD_D01604
Description Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and bronchodilation. Activation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). Elevation of these two molecules induces bronchodilation by relaxation of airway smooth muscles. It is by this mechanism that olodaterol is used for the treatment of chronic obstructive pulmonary disease (COPD) and the progressive airflow obstruction that is characteristic of it. Treatment with bronchodilators helps to mitigate associated symptoms such as shortness of breath, cough, and sputum production. Single doses of olodaterol have been shown to improve forced expiratory volume in 1 sec (FEV1) for 24 h in patients with COPD, allowing once daily dosing. A once-a-day treatment with a LABA has several advantages over short-acting bronchodilators and twice-daily LABAs including improved convenience and compliance and improved airflow over a 24-hour period. Despite similarities in symptoms, olodaterol is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma.
Indications and Usage Olodaterol is indicated for use in chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma.
Marketing Status Prescription
ATC Code R03AC19
DrugBank ID DB09080
KEGG ID D10145
MeSH ID C549647
PubChem ID 11504295
TTD Drug ID D04UTT
NDC Product Code Not Available
Synonyms olodaterol | 6-hydroxy-8-(1-hydroxy-2-((2-(4-methoxyphenyl)-1,1-dimethylethyl)amino)ethyl)-2H-1,4-benzoxazin-3(4H)-one | BI 1744 CL | BI-1744 CL | Striverdi Respimat
Chemical Information
Molecular Formula C21H26N2O5
CAS Registry Number 868049-49-4
SMILES CC(C)(CC1=CC=C(C=C1)OC)NCC(C2=C3C(=CC(=C2)O)NC(=O)CO3)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Arthralgia15.01.02.001--
Atrial fibrillation02.03.03.002--
Back pain15.03.04.005--
Body temperature increased13.15.01.001--Not Available
Bronchitis22.07.01.001; 11.01.09.001--
Chronic obstructive pulmonary disease22.03.01.007--Not Available
Constipation07.02.02.001--
Cough22.02.03.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Gastrointestinal disorder07.11.01.001--Not Available
Infection11.01.08.002--Not Available
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nervous system disorder17.02.10.001--Not Available
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Skin disorder23.03.03.007--Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary tract infection11.01.14.004; 20.08.02.001--
Musculoskeletal discomfort15.03.04.001--Not Available
Lung neoplasm malignant22.08.01.001; 16.19.02.001--Not Available
Connective tissue disorder15.06.01.006--Not Available
Infestation23.09.05.001; 11.09.01.001--Not Available
Mediastinal disorder22.09.03.001--Not Available
The 1th Page    1    Total 1 Pages